IMR Researchers, in collaboration with colleagues, had their research on Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen published online in JAMA on June 26, 2024. (doi:10.1001/jama.2024.9997)
Among people with prostate cancer, transgender women receiving estrogen are more likely to present with high-grade disease vs cisgender men, suggesting potential delayed diagnosis. A possible reason for delayed diagnosis may be the absence of prostate-specific antigen (PSA) reference ranges specific to transgender women receiving gender-affirming hormones. Due to the castrating effects of gender-affirming hormones, PSA, whose production is androgen-regulated, would be expected to be lowered. This study determined PSA values among a nationwide cohort of transgender women without known prostate cancer receiving estrogen, the most common gender-affirming hormone.
Farnoosh Nik-Ahd, MD1; Amanda M. De Hoedt, MS2; Christi Butler, MD1; Jennifer T. Anger, MD, MPH3; Peter R. Carroll, MD, MPH1; Matthew R. Cooperberg, MD, MPH1; Stephen J. Freedland, MD2,4
Author Affiliations: 1Department of Urology, University of California San Francisco; 2Section of Urology, Veterans Affairs Health Care System, Durham, North Carolina; 3Department of Urology, University of California San Diego; 4Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California